These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32664928)

  • 1. Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis.
    Nicholas JA; Edwards NC; Edwards RA; Dellarole A; Grosso M; Phillips AL
    BMC Neurol; 2020 Jul; 20(1):281. PubMed ID: 32664928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
    Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
    J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Ozaki AF; Choi AS; Le QT; Ko DT; Han JK; Park SS; Jackevicius CA
    Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e005969. PubMed ID: 32148102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study.
    Araujo L; Geertsen SS; Amedume A; Higuchi K; van Wingerden J
    Neurol Ther; 2022 Dec; 11(4):1735-1748. PubMed ID: 36152222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
    J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression.
    Mardan J; Hussain MA; Allan M; Grech LB
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1273-1295. PubMed ID: 34464209
    [No Abstract]   [Full Text] [Related]  

  • 7. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data.
    Engmann NJ; Sheinson D; Bawa K; Ng CD; Pardo G
    J Manag Care Spec Pharm; 2021 May; 27(5):639-649. PubMed ID: 33624535
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study).
    Jongen PJ; Hengstman G; Hupperts R; Schrijver H; Gilhuis J; Vliegen JH; Hoogervorst E; van Huizen M; van Munster E; Samijn J; de Schryver E; Siepman T; Tonk M; Zandbergen E; ten Holter J; van der Kruijk R; Borm G
    BMC Neurol; 2011 Mar; 11():40. PubMed ID: 21450086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis.
    Desai RJ; Mahesri M; Gagne JJ; Hurley E; Tong A; Chitnis T; Minden S; Spettell CM; Matlin OS; Shrank WH; Choudhry NK
    J Manag Care Spec Pharm; 2019 Jan; 25(1):113-121. PubMed ID: 30589630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis.
    Yen L; Wu J; Hodgkins PL; Cohen RD; Nichol MB
    J Manag Care Pharm; 2012; 18(9):701-12. PubMed ID: 23206213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence.
    Ferraro D; Camera V; Baldi E; Vacchiano V; Curti E; Guareschi A; Malagù S; Montepietra S; Strumia S; Santangelo M; Caniatti L; Foschi M; Lugaresi A; Granella F; Pesci I; Motti L; Neri W; Immovilli P; Montanari E; Vitetta F; Simone AM; Sola P
    Curr Med Res Opin; 2018 Oct; 34(10):1803-1807. PubMed ID: 29526118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis: A Multiregional Population-Based Study.
    Ng HS; Zhu F; Zhao Y; Yao S; Lu X; Ekuma O; Evans C; Fisk JD; Marrie RA; Tremlett H
    Neurology; 2024 Feb; 102(3):e208006. PubMed ID: 38181306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes.
    Iglay K; Cartier SE; Rosen VM; Zarotsky V; Rajpathak SN; Radican L; Tunceli K
    Curr Med Res Opin; 2015; 31(7):1283-96. PubMed ID: 26023805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence and persistence to self-administered disease-modifying therapies in patients with multiple sclerosis: A multisite analysis.
    Zuckerman AD; DeClercq J; Simonson D; Zagel AL; Turco E; Banks A; Wawrzyniak J; Rightmier E; Blevins A; Choi L
    Mult Scler Relat Disord; 2023 Jul; 75():104738. PubMed ID: 37182475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low.
    Wong J; Gomes T; Mamdani M; Manno M; O'Connor PW
    Can J Neurol Sci; 2011 May; 38(3):429-33. PubMed ID: 21515501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review.
    Fatoye F; Smith P; Gebrye T; Yeowell G
    BMJ Open; 2019 Apr; 9(4):e027049. PubMed ID: 30987990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of smoking on disease activity in multiple sclerosis patients treated with dimethyl fumarate or fingolimod.
    Tanaka E; Watanabe M; Fukumoto S; Masaki K; Yamasaki R; Matsushita T; Isobe N
    Mult Scler Relat Disord; 2023 Feb; 70():104513. PubMed ID: 36689892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.